Niki BioSolutions grants director 8,000 stock options

The award has a staged vesting schedule, with later installments beginning after the merger's effective date.

Rhea-AI Filing Summary

Laura A. Philips, a director of Niki BioSolutions, Inc. (NIKI), acquired 8,000 stock options in a grant on July 22, 2026, with an exercise price of $8.83 per share and an expiration date of July 22, 2036. The grant left her with 8,000 options held directly. Under the stated schedule, 2,000 options vested immediately upon the closing of the merger; the remaining 6,000 vest in three equal quarterly installments of 2,000, starting on the first business day of the first full quarter following the effective date of the merger.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Philips Laura A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	8,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 8,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.

Key Figures

Stock options granted: 8,000 options Exercise price: $8.83 per share Options held directly after grant: 8,000 options +3 more

6 metrics

Stock options granted 8,000 options Grant dated July 22, 2026

Exercise price $8.83 per share For the stock options granted July 22, 2026

Options held directly after grant 8,000 options Reported resulting position

Options vested upon merger closing 2,000 options Vesting schedule

Remaining options 6,000 options Vest in three equal quarterly installments of 2,000 options each

Option expiration date July 22, 2036 Expiration date for the granted options

Key Terms

Stock Options, exercise price, quarterly installments

3 terms

Stock Options financial

"security title: Stock Options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion or exercise price: 8.8300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

quarterly installments financial

"the remaining 6,000 options vest in three equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Laura A. Philips receive from NIKI?

Laura A. Philips, a director of Niki BioSolutions, Inc., acquired a grant of 8,000 stock options on July 22, 2026. The options have an exercise price of $8.83 per share and expire on July 22, 2036.

How do Laura A. Philips's NIKI stock options vest?

2,000 options vested immediately upon the closing of the merger; the remaining 6,000 vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 04:52 PM EDT Accepted by SEC EDGAR 10/21/2026 - 04:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Philips Laura A

(Last) (First) (Middle)

116 VILLAGE BOULEVARD, SUITE 200

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$8.83	07/22/2026		A		8,000		(1)	07/22/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.

	/s/ Laura A. Philips	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)